US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
US8119159B2
(en)
|
1999-02-22 |
2012-02-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
DK1787658T3
(da)
|
2005-11-10 |
2012-06-25 |
Chemi Spa |
Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer
|
AU2007235251B2
(en)
|
2006-04-07 |
2013-02-07 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
KR100816065B1
(ko)
*
|
2006-11-27 |
2008-03-24 |
동국제약 주식회사 |
초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
|
RU2362544C2
(ru)
*
|
2007-04-09 |
2009-07-27 |
Закрытое акционерное общество "Санкт-Петербургский институт фармации" |
Наноэмульсия с биологически активными веществами
|
CA2702135C
(en)
*
|
2007-10-04 |
2013-08-20 |
Daniel Py |
Apparatus and method for formulating and aseptically filling liquid products
|
AU2009244799B2
(en)
*
|
2008-05-07 |
2014-11-20 |
Merrion Research Iii Limited |
Compositions of GnRH related compounds and processes of preparation
|
TWI536999B
(zh)
|
2010-01-13 |
2016-06-11 |
艾普森藥品公司 |
製備持續釋放生長激素抑制素類似物之醫藥組成物之方法
|
US9089484B2
(en)
|
2010-03-26 |
2015-07-28 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
|
EP2576579B1
(en)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
PT2425814E
(pt)
|
2010-09-03 |
2013-09-02 |
Novagali Pharma Sa |
Emulsão de tipo água em óleo para tratamento de uma doença ocular
|
US9107822B2
(en)
|
2010-09-03 |
2015-08-18 |
Santen Sas |
Water-in oil type emulsion for treating a disease of the eye
|
ES2524580T3
(es)
|
2010-09-03 |
2014-12-10 |
Santen Sas |
Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
AU2012204213A1
(en)
|
2011-01-07 |
2013-06-13 |
Merrion Research Iii Limited |
Pharmaceutical compositions of iron for oral administration
|
JP6108628B2
(ja)
|
2011-03-29 |
2017-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Tmprss6遺伝子の発現を阻害する組成物および方法
|
SG10201805199RA
(en)
|
2011-06-02 |
2018-07-30 |
Harvard College |
Methods and Uses for Ex Vivo Tissue Culture Systems
|
CN103890000B
(zh)
|
2011-06-21 |
2017-09-01 |
阿尔尼拉姆医药品有限公司 |
血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
EP3366312A1
(en)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: compositions of matter and methods of treatment
|
EP2724156B1
(en)
|
2011-06-27 |
2017-08-16 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
CN102552138A
(zh)
*
|
2012-02-28 |
2012-07-11 |
大连医科大学 |
口服羟丝肽w/o微乳制剂及其制备方法
|
CN102552187B
(zh)
*
|
2012-02-28 |
2015-10-28 |
大连医科大学 |
口服羟丝肽纳米粒及其制备方法
|
WO2013134267A1
(en)
*
|
2012-03-05 |
2013-09-12 |
Archer Daniels Midland Company |
Microemulsions and uses thereof as delivery systems
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP3336187A1
(en)
|
2012-12-05 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9 irna compositions and methods of use thereof
|
HUE034987T2
(en)
|
2013-03-14 |
2018-05-02 |
Alnylam Pharmaceuticals Inc |
C5 complementary component IRNS preparations and methods for their use
|
CA2918194C
(en)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
AR096203A1
(es)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
|
BR112015029276B1
(pt)
|
2013-05-22 |
2022-07-12 |
Alnylam Pharmaceuticals, Inc |
Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
|
PT2999785T
(pt)
|
2013-05-22 |
2018-07-09 |
Alnylam Pharmaceuticals Inc |
Composições de irna de serpina1 e métodos de uso das mesmas
|
BR112015031278B1
(pt)
|
2013-06-14 |
2022-05-17 |
Akamara Therapeutics, Inc |
Compostos e nanopartículas de platina com base em lipídio, seus processos de preparação, composições farmacêuticas compreendendo os mesmos e seus usos no tratamento de câncer
|
EP2823808A1
(en)
*
|
2013-07-09 |
2015-01-14 |
Ipsen Pharma S.A.S. |
Pharmaceutical composition for a sustained release of lanreotide
|
EP2832361A1
(en)
*
|
2013-07-29 |
2015-02-04 |
Ipsen Pharma S.A.S. |
Aqueous sustained release compositions of LHRH analogs
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
UA124961C2
(uk)
|
2013-10-04 |
2021-12-22 |
Елнілем Фармасьютикалз, Інк. |
ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
EP3960860A3
(en)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
AU2015264038B2
(en)
|
2014-05-22 |
2021-02-11 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
|
KR101686986B1
(ko)
|
2014-07-28 |
2016-12-16 |
에스케이케미칼주식회사 |
류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
AU2015350120B2
(en)
|
2014-11-17 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
US11400139B2
(en)
|
2015-01-20 |
2022-08-02 |
The Children's Medical Center Corporation |
Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing
|
WO2016120378A1
(en)
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Tablets comprising glp-1 agonist and enteric coating
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EA201792263A1
(ru)
|
2015-04-13 |
2018-08-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2016179342A2
(en)
|
2015-05-06 |
2016-11-10 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
CN114525280A
(zh)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
US20180312534A1
(en)
|
2015-10-16 |
2018-11-01 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
SG11201804729RA
(en)
|
2015-12-07 |
2018-07-30 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
WO2019014530A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
LACTATE DEHYDROGENASE A (LDHA) RNAI COMPOSITIONS AND METHODS OF USE
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
JP2021508491A
(ja)
|
2017-12-18 |
2021-03-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
高移動度グループボックス−1(HMGB1)iRNA組成物及びその使用方法
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
KR20220115995A
(ko)
|
2019-12-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CA3179411A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CN116134135A
(zh)
|
2020-04-07 |
2023-05-16 |
阿尔尼拉姆医药品有限公司 |
用于沉默scn9a表达的组合物和方法
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
CA3181400A1
(en)
|
2020-04-27 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
EP4256053A1
(en)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
JP2024508714A
(ja)
|
2021-02-12 |
2024-02-28 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
スーパーオキシドジスムターゼ1-(SOD1-)関連神経変性疾患を治療または予防するためのスーパーオキシドジスムターゼ1(SOD1)iRNA組成物およびその使用方法
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
WO2022212231A2
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
WO2022215899A1
(ko)
*
|
2021-04-08 |
2022-10-13 |
주식회사 티온랩테라퓨틱스 |
서방성 지질 전구 제제
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
CN117561334A
(zh)
|
2021-06-04 |
2024-02-13 |
阿尔尼拉姆医药品有限公司 |
人染色体9开放阅读框72(C9ORF72)iRNA药剂组合物和其使用方法
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|